Regeneron Pharmaceuticals Inc reported that analyzes suggested that its cocktail of antibodies against COVID-19, and similar drugs, may have reduced activity against the omicron variant of the coronavirus.
The drugmaker said the analysis shows that the individual mutations present in the omicron variant indicate “that there may be a reduced neutralizing activity of both vaccine-induced immunity and immunity transmitted by monoclonal antibodies ”.
Further analysis is underway, the company said, adding that there was no direct data proving omicron’s resistance to immunity obtained from vaccines and monoclonal antibodies.
The comments follow statements by the CEO of Moderna Inc, who said COVID-19 vaccines are unlikely to be as effective against the omicron variant as they have previously been with other mutations.
.
Ricardo is a renowned author and journalist, known for his exceptional writing on top-news stories. He currently works as a writer at the 247 News Agency, where he is known for his ability to deliver breaking news and insightful analysis on the most pressing issues of the day.
